🇺🇸 FDA
Patent

US 10822599

Compositions for linking DNA-binding domains and cleavage domains

granted A61PA61P13/12A61P19/00

Quick answer

US patent 10822599 (Compositions for linking DNA-binding domains and cleavage domains) held by Sangamo Therapeutics, Inc. expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61P, A61P13/12, A61P19/00, A61P25/00, A61P25/14